Abstract

For FY13, the Integrated Research Facility in the Division of Clinical Research has significantly increased the level of research facilitation that it provides. Primarily, this support has been directed to facilitating the biodefense and emerging infectious disease research of the Emerging Viral Pathogens section in the Division of Intramural Research, reported separately. In addition, core capabilities of the IRF have been established to include clinical pathology, anatomic pathology, electron microscopy, confocal microscopy, immunology, and cell culture. Rodents were introduced into the facility in Nov 2012 followed by primates in December of the same year. Medical imaging using all four modalities on uninfected animals was initiated in January 2013 followed by infections non-Select Agents in March and aerosol infectivity studies in April, plus influenza and MERS in July.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Clinical Support Services Intramural Research (ZID)
Project #
1ZIDAI009006-05
Application #
8745795
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2013
Total Cost
$19,981,023
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Cooper, Timothy K; Sword, Jennifer; Johnson, Joshua C et al. (2018) New Insights Into Marburg Virus Disease Pathogenesis in the Rhesus Macaque Model. J Infect Dis :
Cline, John Mark; Dugan, Greg; Bourland, John Daniel et al. (2018) Post-Irradiation Treatment with a Superoxide Dismutase Mimic, MnTnHex-2-PyP5+, Mitigates Radiation Injury in the Lungs of Non-Human Primates after Whole-Thorax Exposure to Ionizing Radiation. Antioxidants (Basel) 7:
Logue, James; Tuznik, Kaylie; Follmann, Dean et al. (2018) Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. J Virol Methods 255:84-90
Rimoin, Anne W; Lu, Kai; Bramble, Matthew S et al. (2018) Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection. J Infect Dis 217:223-231
Smith, Darci R; Johnston, Sara C; Piper, Ashley et al. (2018) Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl Trop Dis 12:e0006474
Cooper, Timothy K; Huzella, Louis; Johnson, Joshua C et al. (2018) Histology, immunohistochemistry, and in situ hybridization reveal overlooked Ebola virus target tissues in the Ebola virus disease guinea pig model. Sci Rep 8:1250
Dokubo, Emily Kainne; Wendland, Annika; Mate, Suzanne E et al. (2018) Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report. Lancet Infect Dis 18:1015-1024
Shantha, Jessica G; Mattia, John G; Goba, Augustine et al. (2018) Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. EBioMedicine 30:217-224
Jensen, Kenneth S; Adams, Ricky; Bennett, Richard S et al. (2018) Development of a novel real-time polymerase chain reaction assay for the quantitative detection of Nipah virus replicative viral RNA. PLoS One 13:e0199534
Tamhankar, Manasi; Gerhardt, Dawn M; Bennett, Richard S et al. (2018) Heparan sulfate is an important mediator of Ebola virus infection in polarized epithelial cells. Virol J 15:135

Showing the most recent 10 out of 85 publications